Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 known ✓ | P22460 | 3/20 | 0.57 |
| ▸ | SCN5A known ✓ | Q14524 | 3/20 | 0.57 |
| ▸ | HSD11B1 known ✓ | P28845 | 2/20 | 0.37 |
| ▸ | CASR known ✓ | P41180 | 3/20 | 0.35 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACP3 | P15309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1762349 | 1.00 | KCNA5 (0.57) | KCNA5SCN5AHSD11B1CASRMETAP2 | |
| SCHEMBL1762200 | 0.99 | KCNA5 (0.58) | KCNA5SCN5AHSD11B1CASRMETAP2 | |
| SCHEMBL3574304 | 0.99 | KCNA5 (0.58) | KCNA5SCN5AHSD11B1CASRMETAP2 | |
| SCHEMBL1762342 | 0.99 | KCNA5 (0.58) | KCNA5SCN5AHSD11B1CASRMETAP2 | |
| Hydrochloric Acid SCHEMBL1762316 | 0.78 | SLC18A3 (0.43) | KCNA5SCN5ACASRMETAP2METAP1 | |
| Hydrochloric Acid SCHEMBL1762428 | 0.78 | SLC18A3 (0.43) | KCNA5SCN5ACASRMETAP2METAP1 | |
| Hydrochloric Acid SCHEMBL5949221 | 0.78 | SLC18A3 (0.43) | KCNA5SCN5ACASRMETAP2METAP1 | |
| SCHEMBL2124869 | 0.75 | KCNA5 (0.39) | KCNA5SCN5AHSD11B1METAP2METAP1 | |
| SCHEMBL2122586 | 0.75 | KCNA5 (0.39) | KCNA5SCN5AHSD11B1METAP2METAP1 | |
| SCHEMBL2125605 | 0.75 | KCNA5 (0.39) | KCNA5SCN5AHSD11B1METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188140-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. | 2012-05-29 | — | — | US | disclosed |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2011-05-19 | — | — | US | disclosed |
| US-7820712-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-7674820-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2010-03-09 | — | — | US | disclosed |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090041841-A1 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS | CARDIOME PHARMA CORP. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2008-08-07 | — | — | US | disclosed |
| US-7345086-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-20060135536-A9 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2006-06-22 | — | — | US | disclosed |
| US-20050070552-A1 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2005-03-31 | — | — | US | disclosed |
| WO-2005018635-A2 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2005-03-03 | — | — | WO | disclosed |
| US-20050026993-A1 | Uses of ion channel modulating compounds | CORREVIO CANADA CORP. (CA) | 2005-02-03 | — | — | US | disclosed |
| WO-2004098525-A2 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041841-A1 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS | KCNN3, KCNN2, KCNN1 | KCNA5 78/4885SCN5A 59/4885HSD11B1 3022/4885 |
| US-20050070552-A1 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KCNA5 45/4885SCN5A 71/4885HSD11B1 3797/4885 |
| US-20050026993-A1 | Uses of ion channel modulating compounds | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885HSD11B1 3817/4885 |
| US-20060135536-A9 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KCNA5 45/4885SCN5A 71/4885HSD11B1 3797/4885 |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNN2 | KCNA5 31/4885SCN5A 59/4885HSD11B1 3790/4885 |
| US-20110118329-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885HSD11B1 3817/4885 |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885HSD11B1 3817/4885 |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNJ2 | KCNA5 34/4885SCN5A 64/4885HSD11B1 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.